Healthcare

● Phase 2 VALIANT data showed verekitug's 400mg twice-yearly dose delivered only a 39% exacerbation reduction versus 56% at the 100mg dose, a setback that first sent shares down about 47% in a single session.

● Sana Biotechnology shares have fallen sharply, most recently closing at $3.74, down 8.78%, on unusually lightVolumewith no freshEarningsor clinical disclosure identified as the trigger.

● First Tracks Biotherapeutics shares have fallen sharply, most recently closing at $41.90, down 7.91%, cooling after a rally driven largely by a single-day jump tied to a competitor's positive CD122 data.

● REGENXBIO shares have fallen sharply, most recently closing at $11.06, down 7.99%, two weeks after reporting Q2 2026 results.

● TransCode Therapeutics shares have fallen, most recently closing at $2.97, down 7.48%, carrying a marketCapitalizationof roughly $3.6 million with only about 1.1 million shares outstanding following a 1-for-28 reverse stock split.

● Regentis Biomaterials shares have fallen, most recently closing at $2.06, down 7.62%, with a marketCapitalizationof roughly $10 million.

● Prime Medicine shares have fallen sharply, most recently closing at $3.24, down 8.47%, amid a broad selloff in speculative biotech as long-term Treasury yields rose to their highest level in nearly two decades.